You are here

Clinical Trials: Cord Blood


Body: Conditions:   Hematological Malignancies;   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS)
Intervention:   Drug: NiCord®
Sponsor:   Gamida Cell ltd
Recruiting - verified May 2017
Body: Condition:   Acute Leukemia
Intervention:   Procedure: allogeneic transplant
Sponsor:   Gruppo Italiano Trapianto di Midollo Osseo
Completed - verified August 2017
Body: Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Acute Lymphocytic Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
Interventions:   Device: CliniMACS® CD34 Reagent System;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Rabbit ATG;   Procedure: Double Umbilical Cord Blood Transplantation;   Procedure: Haplo-Identical Cord Transplantation
Sponsor:   Weill Medical College of Cornell University
Terminated - verified August 2017
Body: Condition:   Degeneration Articular Cartilage Knee
Intervention:   Biological: CARTISTEM®
Sponsor:   Medipost Co Ltd.
Active, not recruiting - verified April 2017
Body: Condition:   Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Melphalan;   Procedure: NK Cell Infusion;   Procedure: Stem Cell Infusion;   Drug: G-CSF;   Drug: Elotuzumab;   Drug: Dexamethasone
Sponsors:   M.D. Anderson Cancer Center;   Celgene
Recruiting - verified June 2017
Body: Condition:   Hematopoietic Stem Cell Transplantation
Intervention:   Procedure: Intrabone infusion of umbilical cord blood stem cells
Sponsors:   Henrique Bittencourt, MD, PhD;   Michel Duval, MD;   Pierre Teira, MD;   Sonia Cellot, MD, PhD;   Isabelle Louis, PhD;   Elie Haddad, MD, PhD;   Marie-France Vachon, MScN;   Marion Cortier, PhD
Body: Conditions:   Acute Leukemia of Ambiguous Lineage;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A;   Adult Acute Promyelocytic Leukemia With PML-RARA;   Alkylating Agent-Related Acute Myeloid Leukemia;   Childhood Acute Myeloid Leukemia in Remission;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: Cytarabine;   Procedure: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion;   Biological: Filgrastim;   Drug: Fludarabine Phosphate
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Seattle Children's Research Institute Center for Clinical and Translational Research
Active, not recruiting - verified March 2017
Body: Conditions:   Acute Biphenotypic Leukemia;   Acute Erythroid Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Megakaryoblastic Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Pancytopenia;   Refractory Anemia;   Secondary Acute Myeloid Leukemia
Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Procedure: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2017
Body: Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Interventions:   Drug: Allopurinol;   Drug: Keppra;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Biological: Allogeneic hematopoietic stem cell transplant;   Biological: Filgrastim;   Biological: antithymocyte globulin
Sponsor:   Masonic Cancer Center, University of Minnesota
Body: Conditions:   Leukemia;   Myelodysplastic Syndrome;   Lymphoma
Interventions:   Device: CliniMACS Fractionation system (Arm A);   Device: CliniMACS Fractionation system (Arm B)
Sponsor:   Memorial Sloan Kettering Cancer Center
Recruiting - verified June 2017
Body: Condition:   Infusion Reactions
Intervention:   Biological: unlicensed CBU
Sponsor:   New York Blood Center
Recruiting - verified April 2017
Body: Conditions:   SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
Interventions:   Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine phosphate 30 mg;   Drug: MESNA
Sponsor:   Masonic Cancer Center, University of Minnesota
Body: Condition:   Autism
Interventions:   Biological: Autologous Cord Blood Stem Cells;   Biological: Placebo
Sponsor:   Sutter Health
Completed - verified May 2017
Body: Conditions:   Lysosomal Storage Disease;   Peroxisomal Disorder
Interventions:   Drug: Campath-1H;   Drug: Clofarabine;   Drug: Melphalan;   Radiation: Total Body Irradiation with Marrow Boosting;   Biological: Hematopoietic stem cell transplantation;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil
Sponsor:   Masonic Cancer Center, University of Minnesota
Body: Condition:   Hematologic Malignancies
Interventions:   Biological: ProHema-CB;   Biological: Untreated CB
Sponsor:   Fate Therapeutics
Terminated - verified June 2017